Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, placebo and positive-controlled, dose-escalation study to determine the safety, pharmacodynamics and pharmacokinetics of a single intravenous injection ofHSK3486 in healthy subjects

Next Previous
Trial Profile

A Phase 1, placebo and positive-controlled, dose-escalation study to determine the safety, pharmacodynamics and pharmacokinetics of a single intravenous injection ofHSK3486 in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cipepofol (Primary) ; Propofol
  • Indications Anaesthesia; Sedation
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Acronyms HSK3486 SAD
  • Sponsors Sichuan Haisco Pharmaceutical

Most Recent Events

  • 15 Jan 2021 Results published in the Anesthesia and Analgesia
  • 15 Dec 2014 Addition of a cohort in the dosing schedule and reduction of dose of two other cohorts from 0.648 mg/kg and 0.972 mg/kg to 0.540 mg/kg and 0.648 mg kg respectively.
  • 15 Dec 2014 Planned number of patients changed from 42 to 48, as reported by Australian New Zealand Clinical Trials Registry record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top